Diadema Partners »

Celldex Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $5.1M 137k 37.21

More positions owned by Diadema Partners

Abivax Sa Sponsored Ads Call Option (ABVX)
Viking Therapeutics (VKTX)
Bristol Myers Squibb Put Option (BMY)
Amgen Call Option (AMGN)
United Therapeutics Corporation (UTHR)
Revolution Medicines (RVMD)
Uniqure Nv SHS Put Option (QURE)
Novartis Sponsored Adr Call Option (NVS)
Kodiak Sciences Call Option (KOD)
Capricor Therapeutics Com New Put Option (CAPR)
Cogent Biosciences (COGT)
Bridgebio Pharma Note 1.750% 3/0 (Principal)
Corcept Therapeutics Incorporated Call Option (CORT)
BioMarin Pharmaceutical (BMRN)
Kymera Therapeutics Call Option (KYMR)

View all positions for Diadema Partners

Top funds holding Celldex Therapeutics

Wellington Management Company
BlackRock
Kynam Capital Management
FMR
Vanguard Capital Management
Deep Track Capital
State Street Corporation
Logos Global Management
T. Rowe Price Associates
Geode Capital Management
Eversept Partners
Goldman Sachs Group
Commodore Capital
Bellevue Group
Baker Bros. Advisors

View all funds holding Celldex Therapeutics